Fractyl Health Q2 FY26 net loss narrows to $25.5 million; adjusted EBITDA loss improves to $16.3 million
GUTS•Cash position and runway
Cash and cash equivalents totaled $47.1 million as of June 30, with runway guidance into early 2027.
Q2 results improve year over year
Fractyl Health posted a Q2 net loss of $25.5 million, narrowing from a $27.9 million loss a year earlier.
- R&D expense fell 34.43% to $13.8 million.
- SG&A rose 8.16% to $5.3 million.
- Non-GAAP adjusted EBITDA improved to negative $16.3 million from negative $24.0 million.
REMAIN-1 timeline remains on track
REMAIN-1 Pivotal Cohort topline 6-month randomized data remain on track for early Q4 2026, supporting a potential FDA De Novo submission in late Q4 2026.
